Prof Linda Mileshkin
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
540 Scholarly works
21 Projects
HIGHLIGHTS
2026
Journal article
FAPI-CUP: A prospective cohort study of patients with cancer of unknown primary (CUP) to evaluate a novel radiotracer, fibroblast activated protein (FAPI), targeting cancer-associated fibroblasts for primary site detection.
DOI: 10.1200/jco.2026.44.16_suppl.30722026
Journal article
Updated safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients (pts) with endometrial cancer (EC) or ovarian cancer (OC): Phase 1/2a BLUESTAR study.
DOI: 10.1200/jco.2026.44.16_suppl.55152026
Research grants (ARC, NHMRC, MRFF)
Super-Next: Complete Genome Profiling for Cancer of Unknown Primary
2020
Research grants (ARC, NHMRC, MRFF)
Super-Next: Complete Genome Profiling for Cancer of Unknown Primary
2020
Research grants (ARC, NHMRC, MRFF)
Evaluation of Fibroblastic Activation Protein Inhibitors (FAPI) as a Novel Radiopharmaceutical Targeting Cancer-Associated Fibroblasts for the Diagnosis and Treatment of Patients With Cancer of Unknown Primary: The FAPI-CUP Trial
2015
Journal article
Whole-genome characterization of chemoresistant ovarian cancer
DOI: 10.1038/nature144102013
Journal article
Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary
DOI: 10.1002/path.4251
RECENT SCHOLARLY WORKS
2026
Journal article
Safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients with biliary tract cancer (BTC): A first-in-human phase 1/2a study (BLUESTAR).
DOI: 10.1200/jco.2026.44.16_suppl.41062026
Journal article
IGNITE-Cerala: A phase II signal-seeking trial of ceralasertib targeting recurrent high-grade serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.
DOI: 10.1200/jco.2026.44.16_suppl.55872026
Journal article
Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations
DOI: 10.1016/j.modpat.2026.1010002026
Journal article
Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).
DOI: 10.1200/jco.2026.44.16_suppl.55032026
Journal article
First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion.
DOI: 10.1200/jco.2026.44.16_suppl.30132026
Journal article
Final overall survival (OS) results from the phase 3 ROSELLA trial: Relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (PROC) (GOG-3073, ENGOT-ov72, APGOT-Ov10, and LACOG-0223)
DOI: 10.1016/j.ygyno.2026.02.0222026
Journal article
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial
DOI: 10.1016/j.ijgc.2026.1045562026
Journal article
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
DOI: 10.1016/S0140-6736(26)00462-9